From Analysis:
Epigenetic reprogramming in aging neurons
Investigate mechanisms of epigenetic reprogramming in aging neurons, including DNA methylation changes, histone modification dynamics, chromatin remodeling, and partial reprogramming approaches (e.g., Yamanaka factors) to reverse age-related epigenetic alterations in post-mitotic neurons.
These hypotheses emerged from the same multi-agent debate that produced this hypothesis.
The mitochondrial-nuclear epigenetic cross-talk restoration hypothesis centers on the coordinated dysfunction of SIRT3, a critical NAD+-dependent deacetylase localized primarily to the mitochondrial matrix, and its intricate communication network with nuclear chromatin remodeling complexes. SIRT3 serves as the primary mitochondrial deacetylase, regulating over 300 mitochondrial proteins through lysine deacetylation, including key components of the electron transport chain complexes I, II, and III, as well as metabolic enzymes such as acetyl-CoA synthetase 2 (ACSS2), long-chain acyl-CoA dehydrogenase (LCAD), and manganese superoxide dismutase (MnSOD).
Interactive 3D viewer powered by RCSB PDB / Mol*. Use mouse to rotate, scroll to zoom.
Neurodegenerative diseases are a group of pathological conditions that cause motor incordination (jerking movements), cognitive and memory impairments result from degeneration of neurons in a specific area of the brain. Oxidative stress, mitochondrial dysfunction, excitotoxicity, neuroinflammation, neurochemical imbalance and histone deacetylase enzymes (HDAC) are known to play a crucial role in neurodegeneration. HDAC is classified into four categories (class I, II, III and class IV) depending upon their location and functions. HDAC1 and 2 are involved in neurodegeneration, while HDAC3-11 and class III HDACs are beneficial as neuroprotective. HDACs are localized in different parts of the brain- HDAC1 (hippocampus and cortex), HDAC2 (nucleus), HDAC3, 4, 5, 7 and 9 (nucleus and cytoplasm), HDAC6 & HDAC7 (cytoplasm) and HDAC11 (Nucleus, cornus ammonis 1 and spinal cord). In pathological conditions, HDAC up-regulates glutamate, phosphorylation of tau, and glial fibrillary acidic proteins
Mitochondrial dysfunction is critically involved in the degeneration of dopamine (DA) neurons in the substantia nigra, a common pathological feature of Parkinson's disease (PD). Previous studies have demonstrated that the NAD+-dependent acetylase Sirtuin 3 (SIRT3) participates in maintaining mitochondrial function and is downregulated in aging-related neurodegenerative disorders. The exact mechanism of action of SIRT3 on mitochondrial bioenergetics in PD pathogenesis, however, has not been fully described. In this study, we investigated the regulatory role of SIRT3-mediated deacetylation of mitochondrial complex II (succinate dehydrogenase) subunit A (SDHA) and its effect on neuronal cell survival in rotenone (ROT)-induced rat and differentiated MN9D cell models. The results revealed that SIRT3 activity was suppressed in both in vivo and in vitro PD models. Accompanying this downregulation of SIRT3 was the hyperacetylation of SDHA, impaired activity of mitochondrial complex II, and dec
Caloric restriction (CR), fasting, and exercise have long been recognized for their neuroprotective and lifespan-extending properties; however, the underlying mechanisms of these phenomena remain elusive. Such extraordinary benefits might be linked to the activation of sirtuins. In mammals, the sirtuin family has seven members (SIRT1-7), which diverge in tissue distribution, subcellular localization, enzymatic activity, and targets. SIRT1, SIRT2, and SIRT3 have deacetylase activity. Their dependence on NAD(+) directly links their activity to the metabolic status of the cell. High NAD(+) levels convey neuroprotective effects, possibly via activation of sirtuin family members. Mitochondrial sirtuin 3 (SIRT3) has received much attention for its role in metabolism and aging. Specific small nucleotide polymorphisms in Sirt3 are linked to increased human lifespan. SIRT3 mediates the adaptation of increased energy demand during CR, fasting, and exercise to increased production of energy equiv
Sirtuin3 (SIRT3) is a nicotinamide adenine dinucleotide (NAD+)-dependent protein deacetylase located in the mitochondria, which mainly regulates the acetylation of mitochondrial proteins. In addition, SIRT3 is involved in critical biological processes, including oxidative stress, inflammation, DNA damage, and apoptosis, all of which are closely related to the progression of liver disease. Liver fibrosis characterized by the deposition of extracellular matrix is a result of long termed or repeated liver damage, frequently accompanied by damaged hepatocytes, the recruitment of inflammatory cells, and the activation of hepatic stellate cells. Based on the functions and pharmacology of SIRT3, we will review its roles in liver fibrosis from three aspects: First, the main functions and pharmacological effects of SIRT3 were investigated based on its structure. Second, the roles of SIRT3 in major cells in the liver were summarized to reveal its mechanism in developing liver fibrosis. Last, dru
Heart failure causes significant morbidity and mortality worldwide. The underlying mechanisms and pathological changes associated with heart failure are exceptionally complex. Despite recent advances in heart failure research, treatment outcomes remain poor. The sirtuin family member sirtuin-3 (SIRT3) is involved in several key biological processes, including ATP production, catabolism, and reactive oxygen species detoxification. In addition to its role in metabolism, SIRT3 regulates cell death and survival and has been implicated in the pathogenesis of cardiovascular diseases. Emerging evidence also shows that SIRT3 can protect cardiomyocytes from hypertrophy, ischemia-reperfusion injury, cardiac fibrosis, and impaired angiogenesis. In this review article, we summarize the recent advances in SIRT3 research and discuss the role of SIRT3 in heart failure. We also discuss the potential use of SIRT3 as a therapeutic target in heart failure.
Alzheimer's disease (AD) is the most common neurodegenerative disease, and its incidence is increasing worldwide with increased lifespan. Currently, there is no effective treatment to cure or prevent the progression of AD, which indicates the need to develop novel therapeutic targets and agents. Sirtuins, especially SIRT3, a mitochondrial deacetylase, are NAD-dependent histone deacetylases involved in aging and longevity. Accumulating evidence indicates that SIRT3 dysfunction is strongly associated with pathologies of AD, hence, therapeutic modulation of SIRT3 activity may be a novel application to ameliorate the pathologies of AD. Natural products commonly used in traditional medicine have wide utility and appear to have therapeutic benefits for the treatment of neurodegenerative diseases such as AD. The present review summarizes the currently available natural SIRT3 activators and their potentially neuroprotective molecular mechanisms of action that make them a promising agent in the
Serine metabolism is involved in the fate decisions of immune cells; however, whether and how de novo serine synthesis shapes innate immune cell function remain unknown. Here, we first demonstrated that inflammatory macrophages have high expression of phosphoglycerate dehydrogenase (PHGDH, the rate-limiting enzyme of de novo serine synthesis) via nuclear factor κB signaling. Notably, the pharmacological inhibition or genetic modulation of PHGDH limits macrophage interleukin (IL)-1β production through NAD+ accumulation and subsequent NAD+-dependent SIRT1 and SIRT3 expression and activity. Mechanistically, PHGDH not only sustains IL-1β expression through H3K9/27 acetylation-mediated transcriptional activation of Toll-like receptor 4 but also supports IL-1β maturation via NLRP3-K21/22/24/ASC-K21/22/24 acetylation-mediated activation of the NLRP3 inflammasome. Moreover, mice with myeloid-specific depletion of Phgdh show alleviated inflammatory responses in lipopolysaccharide-induced system
In recent years, epigenetic modifications have been widely researched. As humans age, environmental and genetic factors may drive inflammation and immune responses by influencing the epigenome, which can lead to abnormal autoimmune responses in the body. Currently, an increasing number of studies have emphasized the important role of epigenetic modification in the progression of autoimmune diseases. Sirtuins (SIRTs) are class III nicotinamide adenine dinucleotide (NAD)-dependent histone deacetylases and SIRT-mediated deacetylation is an important epigenetic alteration. The SIRT family comprises seven protein members (namely, SIRT1-7). While the catalytic core domain contains amino acid residues that have remained stable throughout the entire evolutionary process, the N- and C-terminal regions are structurally divergent and contribute to differences in subcellular localization, enzymatic activity and substrate specificity. SIRT1 and SIRT2 are localized in the nucleus and cytoplasm. SIRT
Maintaining metabolic homeostasis is essential for cellular and organismal health throughout life. Multiple signaling pathways that regulate metabolism also play critical roles in aging, such as PI3K/AKT, mTOR, AMPK, and sirtuins (SIRTs). Among them, sirtuins are known as a protein family with versatile functions, such as metabolic control, epigenetic modification and lifespan extension. Therefore, by understanding how sirtuins regulate metabolic processes, we can start to understand how they slow down or accelerate biological aging from the perspectives of metabolic regulation. Here, we review the biology of SIRT3, SIRT4, and SIRT5, known as the mitochondrial sirtuins due to their localization in the mitochondrial matrix. First, we will discuss canonical pathways that regulate metabolism more broadly and how these are integrated with aging regulation. Then, we will summarize the current knowledge about functional differences between SIRT3, SIRT4, and SIRT5 in metabolic control and int
BACKGROUND: Exercise is an effective nonpharmacological strategy to alleviate diabetic cardiomyopathy (DCM) through poorly defined mechanisms. FGF21 (fibroblast growth factor 21), a peptide hormone with pleiotropic benefits on cardiometabolic homeostasis, has been identified as an exercise responsive factor. This study aims to investigate whether FGF21 signaling mediates the benefits of exercise on DCM, and if so, to elucidate the underlying mechanisms. METHODS: The global or hepatocyte-specific FGF21 knockout mice, cardiomyocyte-selective β-klotho (the obligatory co-receptor for FGF21) knockout mice, and their wild-type littermates were subjected to high-fat diet feeding and injection of streptozotocin to induce DCM, followed by a 6-week exercise intervention and assessment of cardiac functions. Cardiac mitochondrial structure and function were assessed by electron microscopy, enzymatic assays, and measurements of fatty acid oxidation and ATP production. Human induced pluripotent stem
Aging is an inherent phenomenon that is highly important in the pathological development of numerous diseases. Aging is a multidimensional phenomenon characterized by the progressive impairment of various cellular structures and organelle functions. The basis of human organ senescence is cellular senescence. Currently, with the increase in human life expectancy and the increasing proportion of the elderly population, the economic burden of diseases related to aging is becoming increasingly heavy worldwide, and an in-depth study of the mechanism of cellular aging is urgently needed. Aging, a multifactor-driven biological process, is closely related to mitochondrial dysfunction, which is the core pathological basis of a variety of age-related diseases. This article systematically reviews the molecular pathways by which mitochondrial dysfunction drives aging through multidimensional mechanisms such as metabolic reprogramming, epigenetic regulation, telomere damage, autophagy imbalance, an
Neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis and frontotemporal dementia represent a significant global health burden with limited therapeutic options. Current treatments are primarily symptomatic and fail to modify disease progression, emphasizing the urgent need for novel, mechanism-based interventions. Recent advances in molecular neuroscience have identified several non-classical pathogenic pathways, including neuroinflammation, mitochondrial dysfunction, impaired autophagy and proteostasis, synaptic degeneration and non-coding RNA dysregulation. In this focused review, we highlight emerging molecular targets such as TREM2, NLRP3, mTOR, TFEB, PINK1 and SIRT3, which offer promising avenues for therapeutic intervention. We also address challenges in target validation and translational drug development, while proposing future research directions that may facilitate the design of more effective treatme
Aging is an extremely significant risk associated with neurodegeneration. The most prevalent neurodegenerative disorders (NDs), such as Alzheimer's disease (AD) are distinguished by the prevalence of proteinopathy, aberrant glial cell activation, oxidative stress, neuroinflammation, defective autophagy, cellular senescence, mitochondrial dysfunction, epigenetic changes, neurogenesis suppression, increased blood-brain barrier permeability, and intestinal dysbiosis that is excessive for the patient's age. Substantial body studies have documented a close relationship between gut microbiota and AD, and restoring a healthy gut microbiota may reduce or even ameliorate AD symptoms and progression. Thus, control of the microbiota in the gut has become an innovative model for clinical management of AD, and rising emphasis is focused on finding new techniques for preventing and/or managing the disease. The etiopathogenesis of gut microbiota in driving AD progression and supplementing postbiotics
The translational gap to treatments based on gene therapy has been reduced in recent years because of improvements in gene editing tools, such as the CRISPR/Cas9 system and its variations. This has allowed the development of more precise therapies for neurodegenerative diseases, where access is privileged. As a result, engineering of complexes that can access the central nervous system (CNS) with the least potential inconvenience is fundamental. In this review article, we describe current alternatives to generate systems based on CRISPR/Cas9 that can cross the blood-brain barrier (BBB) and may be used further clinically to improve treatment for neurodegeneration in Parkinson's and Alzheimer's disease (AD).
Sirtuins are NAD+ dependent enzymes that have a predominant role in neurodegenerative disorders and also regulate the inflammatory process, protein aggregation, etc. The relationships between sirtuins with that of the nervous system and neurodegeneration, are widely studied. Sirtuins have a strong role in metabolic syndrome in mitochondria also. The activities of sirtuins can be altered by using small molecules that would be developed into drugs and it is proven that the manipulation of SIRT1 activity influences neurodegenerative disease models. They are interesting since using small molecules, which would be developed into a drug, it is feasible to alter the activities of sirtuins. Different functions of sirtuins depend upon their subcellular localization. In this review paper, we discuss different sirtuins, differential expression of sirtuins, and expression of sirtuin in the brain and briefly explains Sirtuin3 (SIRT3).
Sirtuins are highly conserved NAD+ dependent class III histone deacetylases and catalyze deacetylation and ADP ribosylation of a number of non-histone proteins. Since, they require NAD+ for their activity, the cellular level of Sirtuins represents redox status of the cells and thereby serves as bona fide metabolic stress sensors. Out of seven homologues of Sirtuins identified in mammals, SIRT3, 4 & 5 have been found to be localized and active in mitochondria. During recent past, clusters of protein substrates for SIRT3 have been identified in mitochondria and thereby advocating SIRT3 as the main mitochondrial Sirtuin which could be involved in protecting stress induced mitochondrial integrity and energy metabolism. As mitochondrial dysfunction underlies the pathogenesis of almost all neurodegenerative diseases, a role of SIRT3 becomes an arguable speculation in such brain disorders. Some recent findings demonstrate that SIRT3 over expression could prevent neuronal derangements in certa
Perfect! Now I have sufficient evidence to generate novel therapeutic hypotheses. Let me create comprehensive, mechanistic hypotheses based on the current literature.
Based on the current research on epigenetic reprogramming in aging neurons, I'll generate novel therapeutic hypotheses that address key knowledge gaps and propose innovative mechanistic approaches:
Based on my analysis, here are the critical weaknesses and concerns for each hypothesis:
Specific Weaknesses:
Based on my analysis of the literature and drug development landscape, here's a comprehensive assessment of the practical feasibility for each therapeutic hypothesis:
Druggability Assessment: POOR
| Event | Price | Change | Source | Time | |
|---|---|---|---|---|---|
| 📄 | New Evidence | $0.472 | ▲ 2.4% | evidence_batch_update | 2026-04-13 02:18 |
| 📄 | New Evidence | $0.461 | ▲ 2.9% | evidence_batch_update | 2026-04-13 02:18 |
| ⚖ | Recalibrated | $0.448 | ▼ 1.6% | 2026-04-12 18:34 | |
| ⚖ | Recalibrated | $0.456 | ▼ 2.2% | 2026-04-12 10:15 | |
| ⚖ | Recalibrated | $0.466 | ▼ 1.3% | 2026-04-10 15:58 | |
| ⚖ | Recalibrated | $0.472 | ▲ 1.6% | 2026-04-10 14:28 | |
| ⚖ | Recalibrated | $0.465 | ▲ 2.5% | 2026-04-08 18:39 | |
| ⚖ | Recalibrated | $0.454 | ▲ 2.6% | 2026-04-06 04:04 | |
| ⚖ | Recalibrated | $0.442 | ▼ 0.7% | 2026-04-04 16:38 | |
| ⚖ | Recalibrated | $0.446 | ▼ 2.4% | 2026-04-04 16:02 | |
| 📄 | New Evidence | $0.456 | ▲ 2.8% | evidence_batch_update | 2026-04-04 09:08 |
| ⚖ | Recalibrated | $0.444 | ▼ 2.4% | 2026-04-03 23:46 | |
| ⚖ | Recalibrated | $0.455 | ▲ 1.7% | 2026-04-02 21:55 | |
| ⚖ | Recalibrated | $0.447 | ▼ 1.7% | market_recalibrate | 2026-04-02 19:14 |
| 💬 | Debate Round | $0.455 | ▲ 5.1% | debate_engine | 2026-04-02 17:18 |
Molecular pathway showing key causal relationships underlying this hypothesis
graph TD
SIRT1["SIRT1"] -->|associated with| SIRT3["SIRT3"]
SIRT3_1["SIRT3"] -->|regulates| mitochondria["mitochondria"]
SIRT3_2["SIRT3"] -->|therapeutic target| neurodegeneration["neurodegeneration"]
SIRT3_3["SIRT3"] -->|associated with| neurodegeneration_4["neurodegeneration"]
SIRT3_5["SIRT3"] -->|participates in| Sirtuin_3___mitochondrial["Sirtuin-3 / mitochondrial deacetylation"]
PARP1["PARP1"] -->|co discussed| SIRT3_6["SIRT3"]
SIRT3_7["SIRT3"] -->|co discussed| TAU["TAU"]
APOE4["APOE4"] -->|co discussed| SIRT3_8["SIRT3"]
SIRT3_9["SIRT3"] -->|co discussed| BRD4["BRD4"]
SIRT3_10["SIRT3"] -->|co discussed| OCT4["OCT4"]
SIRT3_11["SIRT3"] -->|co discussed| BMAL1["BMAL1"]
SIRT3_12["SIRT3"] -->|co discussed| HDAC3["HDAC3"]
SIRT3_13["SIRT3"] -->|co discussed| SIRT1_14["SIRT1"]
SIRT3_15["SIRT3"] -->|co discussed| TET2["TET2"]
BRD4_16["BRD4"] -->|co discussed| SIRT3_17["SIRT3"]
style SIRT1 fill:#ce93d8,stroke:#333,color:#000
style SIRT3 fill:#ce93d8,stroke:#333,color:#000
style SIRT3_1 fill:#ce93d8,stroke:#333,color:#000
style mitochondria fill:#81c784,stroke:#333,color:#000
style SIRT3_2 fill:#ce93d8,stroke:#333,color:#000
style neurodegeneration fill:#ef5350,stroke:#333,color:#000
style SIRT3_3 fill:#ce93d8,stroke:#333,color:#000
style neurodegeneration_4 fill:#ef5350,stroke:#333,color:#000
style SIRT3_5 fill:#ce93d8,stroke:#333,color:#000
style Sirtuin_3___mitochondrial fill:#81c784,stroke:#333,color:#000
style PARP1 fill:#ce93d8,stroke:#333,color:#000
style SIRT3_6 fill:#ce93d8,stroke:#333,color:#000
style SIRT3_7 fill:#ce93d8,stroke:#333,color:#000
style TAU fill:#ce93d8,stroke:#333,color:#000
style APOE4 fill:#ce93d8,stroke:#333,color:#000
style SIRT3_8 fill:#ce93d8,stroke:#333,color:#000
style SIRT3_9 fill:#ce93d8,stroke:#333,color:#000
style BRD4 fill:#ce93d8,stroke:#333,color:#000
style SIRT3_10 fill:#ce93d8,stroke:#333,color:#000
style OCT4 fill:#ce93d8,stroke:#333,color:#000
style SIRT3_11 fill:#ce93d8,stroke:#333,color:#000
style BMAL1 fill:#ce93d8,stroke:#333,color:#000
style SIRT3_12 fill:#ce93d8,stroke:#333,color:#000
style HDAC3 fill:#ce93d8,stroke:#333,color:#000
style SIRT3_13 fill:#ce93d8,stroke:#333,color:#000
style SIRT1_14 fill:#ce93d8,stroke:#333,color:#000
style SIRT3_15 fill:#ce93d8,stroke:#333,color:#000
style TET2 fill:#ce93d8,stroke:#333,color:#000
style BRD4_16 fill:#ce93d8,stroke:#333,color:#000
style SIRT3_17 fill:#ce93d8,stroke:#333,color:#000
neurodegeneration | 2026-04-04 | completed